City
Epaper

Too much 'giloy' can do more harm than good: Study

By IANS | Updated: January 16, 2022 10:50 IST

Lucknow, Jan 16 When the first wave of Covid struck, know-it-all doctors and 'medical experts' claimed that 'giloy' ...

Open in App

Lucknow, Jan 16 When the first wave of Covid struck, know-it-all doctors and 'medical experts' claimed that 'giloy' was an immunity booster that would help fight the virus.

Almost overnight, the sales of Giloy rocketed and people started taking it without any medical consultation.

Now two years later, a study recently published in Hepatology Communications, the official journal of the American Association for the Study of Liver Disease, has found that consumption of 'giloy' without prescription and monitoring can cause damage to organs such as the liver.

The study was conducted by Liver Research Club of India at 13 medical centres including King George's Medical University (KGMU).

Giloy, also known as 'Amrita' or 'Guduchi' in Hindi, is an herb that helps improve digestion and boost immunity. It has heart-shaped leaves that resemble betel leaves. All parts of the plant are used in Ayurvedic medicine. However, the stem is thought to have the most beneficial compounds.

The study was conducted on 43 patients 23 females and 20 males who reported symptoms of jaundice. Clinical findings revealed that all patients were suffering from chronic liver disease or liver failure.

Doctors also found that each of the patients had a history of taking a concoction of giloy.

Dr Ajay Kumar Patwa, associate professor of gastroenterology at KGMU, said, "We found that giloy was the main cause of liver issues in 67.4 per cent (29) patients as there was no other factor like excessive alcohol consumption, diabetes, thyroid, hypertension or any other etiological reason. The remaining patients consumed alcohol regularly and had comorbidities, hence they were not included among those in whom giloy was the main cause."

"Most of these patients had consumed the herbal drug without prescription or taken unprescribed doses for an average 46 days. This generated common antinuclear antibodies which started attacking liver cells and induced acute hepatitis with autoimmune hepatitis-like features," said Prof Patwa.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: lucknowindiaHepatology communicationsAmerican association for the study of liver diseaseAjay kumar patwa
Open in App

Related Stories

TechnologyHow To Effortlessly Transfer Data from Android to iPhone Using Apple’s Move to iOS App

NationalUttar Pradesh Shocker: Man Arrested for Sexually Assaulting Stray Dog in Lucknow

NationalDonald Trump Imposes Additional 25% Tariff on India, Total Tariff Now 50%

TechnologyWill the Government Have to Offer More Incentives on EVs? NITI Aayog Raises Concerns Over Slow Sales Growth

OpinionsWhy is Trump So Upset with India?

Health Realted Stories

HealthCentral public sector enterprise HLL to represent India at FIGO 2025 in South Africa

HealthTripura CM calls for greater awareness on blood, organ donation

HealthBank denies electrical fault at Kancheepuram ATM after shock complaint

HealthJapan reports 135 cases of potentially fatal tick-borne disease in 2025

HealthPollution-led respiratory illness in Delhi: 68,411 cases, 10,819 hospital admissions in 2024